Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …

Alzheimer's disease (AD) is a prevalently found tauopathy characterized by memory loss
and cognitive insufficiency. AD is an age-related neurodegenerative disease with two major …

Alzheimer's disease is characterized by the histopathological presence of amyloid-β
plaques and tau-containing neurofibrillary tangles. Microglial activation is also a recognized …

Tracking longitudinal tau tangles accumulation across the Alzheimer's disease continuum is
crucial to better understand the natural history of tau pathology and for clinical trials …

Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and
nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as …

Background Imaging agents capable of quantifying the brain's tau aggregates will allow a
more precise staging of Alzheimer's disease (AD). The aim of the present study was to …

Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying
individuals as “positive” or “negative” for biomarkers related to the core pathology of β …

Alzheimer's disease (AD) differentially and specifically affects brain regions and neuronal
cell types in a predictable pattern. Damage to the brain appears to spread and worsens with …